Pharmacotherapy effects on smoking cessation vary with nicotine metabolism gene (CYP2A6)

Addiction

Volumn 109, Issue 1, 2014, Pages 128-137

  Chen, Li Shiun ^a   Bloom, A Joseph ^a   Baker, Timothy B ^b   Smith, Stevens S ^b   Piper, Megan E ^b   Martinez, Maribel ^a   Saccone, Nancy ^a   Hatsukami, Dorothy ^c   Goate, Alison ^a   Bierut, Laura ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Metabolism; Nicotine; Pharmacogenetics; Smoking cessation

Indexed keywords

AMFEBUTAMONE; CHRNA5 PROTEIN, HUMAN; CYP2A6 PROTEIN, HUMAN; CYTOCHROME P450 2A6; DOPAMINE UPTAKE INHIBITOR; NERVE PROTEIN; NICOTINE; NICOTINE GUM; NICOTINIC RECEPTOR;

ADULT; CONTROLLED STUDY; DRUG THERAPY; FEMALE; GENETICS; HUMAN; MALE; METABOLISM; MIDDLE AGED; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PROCEDURES; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SMOKING; SMOKING CESSATION; TREATMENT OUTCOME;

ADULT; BASE SEQUENCE; BUPROPION; CYTOCHROME P-450 CYP2A6; DOPAMINE UPTAKE INHIBITORS; FEMALE; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; NERVE TISSUE PROTEINS; NICOTINE; PROPORTIONAL HAZARDS MODELS; RECEPTORS, NICOTINIC; RECURRENCE; SMOKING; SMOKING CESSATION; TOBACCO USE CESSATION PRODUCTS; TREATMENT OUTCOME;

EID: 84890136969     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/add.12353     Document Type: Article

References (35)

1. Chen L. S., Baker T. B., Piper M. E., Breslau N., Cannon D. S., Doheny K. F. etal. Interplay of genetic risk factors (CHRNA5-CHRNA3-CHRNB4) and cessation treatments in smoking cessation success. Am J Psychiatry 2012; 169: 735-742.
2. Liu J. Z., Tozzi F., Waterworth D. M., Pillai S. G., Muglia P., Middleton L. etal. Meta-analysis and imputation refines the association of 15q25 with smoking quantity. Nat Genet 2010; 42: 436-440.
3. Saccone N. L., Culverhouse R. C., Schwantes-An T. H., Cannon D. S., Chen X., Cichon S. etal. Multiple independent loci at chromosome 15q25.1 affect smoking quantity: a meta-analysis and comparison with lung cancer and COPD. PLoS Genet 2010; 6: pii: e1001053. doi: 10.1371/journal.pgen.1001053.
4. Tobacco and Genetics Consortium (TAG). Genome-wide meta-analyses identify multiple loci associated with smoking behavior. Nat Genet 2010; 42: 441-447.
5. Thorgeirsson T. E., Gudbjartsson D. F., Surakka I., Vink J. M., Amin N., Geller F. etal. Sequence variants at CHRNB3-CHRNA6 and CYP2A6 affect smoking behavior. Nat Genet 2010; 42: 448-453.
6. Bergen A. W., Javitz H. S., Krasnow R., Nishita D., Michel M., Conti D. V. etal. Nicotinic acetylcholine receptor variation and response to smoking cessation therapies. Pharmacogenet Genomics 2013; 23: 94-103.
7. Bloom A. J., Harari O., Martinez M., Madden P. A., Martin N. G., Montgomery G. W. etal. Use of a predictive model derived from in vivo endophenotype measurements to demonstrate associations with a complex locus, CYP2A6. Hum Mol Genet 2012; 21: 3050-3062.
8. Fujieda M., Yamazaki H., Saito T., Kiyotani K., Gyamfi M. A., Sakurai M. etal. Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male Japanese smokers. Carcinogenesis 2004; 25: 2451-2458.
9. Schoedel K. A., Hoffmann E. B., Rao Y., Sellers E. M., Tyndale R. F. Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians. Pharmacogenetics 2004; 14: 615-626.
10. Haberl M., Anwald B., Klein K., Weil R., Fuss C., Gepdiremen A. etal. Three haplotypes associated with CYP2A6 phenotypes in Caucasians. Pharmacogenet Genomics 2005; 15: 609-624.
11. Bloom J., Hinrichs A. L., Wang J. C., von Weymarn L. B., Kharasch E. D., Bierut L. J. etal. The contribution of common CYP2A6 alleles to variation in nicotine metabolism among European-Americans. Pharmacogenet Genomics 2011; 21: 403-416.
12. Lerman C., Jepson C., Wileyto E. P., Patterson F., Schnoll R., Mroziewicz M. etal. Genetic variation in nicotine metabolism predicts the efficacy of extended-duration transdermal nicotine therapy. Clin Pharmacol Ther 2010; 87: 553-557.
13. Patterson F., Schnoll R. A., Wileyto E. P., Pinto A., Epstein L. H., Shields P. G. etal. Toward personalized therapy for smoking cessation: a randomized placebo-controlled trial of bupropion. Clin Pharmacol Ther 2008; 84: 320-325.
14. Schnoll R. A., Patterson F., Wileyto E. P., Tyndale R. F., Benowitz N., Lerman C. Nicotine metabolic rate predicts successful smoking cessation with transdermal nicotine: a validation study. Pharmacol Biochem Behav 2009; 92: 6-11.
15. Benowitz N. L., Pomerleau O. F., Pomerleau C. S., Jacob P. III. Nicotine metabolite ratio as a predictor of cigarette consumption. Nicotine Tob Res 2003; 5: 621-624.
16. Ray R., Tyndale R. F., Lerman C. Nicotine dependence pharmacogenetics: role of genetic variation in nicotine-metabolizing enzymes. J Neurogenet 2009; 23: 252-261.
17. Piper M. E., Smith S. S., Schlam T. R., Fiore M. C., Jorenby D. E., Fraser D. etal. A randomized placebo-controlled clinical trial of 5 smoking cessation pharmacotherapies. Arch Gen Psychiatry 2009; 66: 1253-1262.
18. Heatherton T. F., Kozlowski L. T., Frecker R. C., Fagerstrom K. O. The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br J Addict 1991; 86: 1119-1127.
19. Piper M. E., Federman E. B., McCarthy D. E., Bolt D. M., Smith S. S., Fiore M. C. etal. Efficacy of bupropion alone and in combination with nicotine gum. Nicotine Tob Res 2007; 9: 947-954.
20. Sobell L. C., Sobell M. B. Timeline follow-back: a technique for assessing self-reported alcohol consumption. In: Litten R. Z., Allen J., editors. Measuring Alcohol Consumption: Psychosocial and Biological Methods. Totowa, NJ: Human Press; 1992, pp. 41-72.
21. St Helen G., Novalen M., Heitjan D. F., Dempsey D., Jacob P., 3rd, Aziziyeh A. etal. Reproducibility of the nicotine metabolite ratio in cigarette smokers. Cancer Epidemiol Biomarkers Prev 2012; 21: 1105-1114.
22. Lerman C., Tyndale R., Patterson F., Wileyto E. P., Shields P. G., Pinto A. etal. Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation. Clin Pharmacol Ther 2006; 79: 600-608.
23. Faucette S. R., Hawke R. L., Lecluyse E. L., Shord S. S., Yan B., Laethem R. M. etal. Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. Drug Metab Dispos 2000; 28: 1222-1230.
24. Benowitz N. L., Zhu A. Z., Tyndale R. F., Dempsey D., Jacob P. III. Influence of CYP2B6 genetic variants on plasma and urine concentrations of bupropion and metabolites at steady state. Pharmacogenet Genomics 2013; 23: 135-141.
25. Pogue J., Yusuf S. Overcoming the limitations of current meta-analysis of randomised controlled trials. Lancet 1998; 351: 47-52.
26. Riet G. T., Bachmann L. M., Kessels A. G., Khan K. S. Individual patient data meta-analysis of diagnostic studies: opportunities and challenges. Evid Based Med 2013; 18: 165-169.
27. Wassenaar C. A., Dong Q., Wei Q., Amos C. I., Spitz M. R., Tyndale R. F. Relationship between CYP2A6 and CHRNA5-CHRNA3-CHRNB4 variation and smoking behaviors and lung cancer risk. J Natl Cancer Inst 2011; 103: 1342-1346.
28. Baker T. B., Breslau N., Covey L., Shiffman S. DSM criteria for tobacco use disorder and tobacco withdrawal: a critique and proposed revisions for DSM-5. Addiction 2012; 107: 263-275.
29. Kubota T., Nakajima-Taniguchi C., Fukuda T., Funamoto M., Maeda M., Tange E. etal. CYP2A6 polymorphisms are associated with nicotine dependence and influence withdrawal symptoms in smoking cessation. Pharmacogenomics J 2006; 6: 115-119.
30. Rubinstein M. L., Benowitz N. L., Auerback G. M., Moscicki A. B. Rate of nicotine metabolism and withdrawal symptoms in adolescent light smokers. Pediatrics 2008; 122: e643-647.
31. Etter J. F., Perneger T. V. Measurement of self reported active exposure to cigarette smoke. J Epidemiol Commun Health 2001; 55: 674-680.
32. Perez-Stable E. J., Benowitz N. L., Marin G. Is serum cotinine a better measure of cigarette smoking than self-report? Prev Med 1995; 24: 171-179.
33. McDonagh E. M., Wassenaar C., David S. P., Tyndale R. F., Altman R. B., Whirl-Carrillo M. etal. PharmGKB summary: very important pharmacogene information for cytochrome P-450, family 2, subfamily A, polypeptide 6. Pharmacogenet Genomics 2012; 22: 695-708.
34. Uhl G. R., Liu Q. R., Drgon T., Johnson C., Walther D., Rose J. E. etal. Molecular genetics of successful smoking cessation: convergent genome-wide association study results. Arch Gen Psychiatry 2008; 65: 683-693.
35. Lotrich F. E. The emerging potential of pharmacogenetics in psychiatry. Am J Psychiatry 2012; 169: 681-683.